Related Experiment Video
Updated: Nov 14, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Preclinical Studies of PROTACs in Hematological Malignancies
1Department of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Abstract:
Incorrectly expressed or mutated proteins associated with hematologic malignancies have been generally targeted by chemotherapy using small-molecule inhibitors or monoclonal antibodies. But the majority of these intracellular proteins are without active sites and antigens. PROTACs, proteolysis targeting chimeras, are bifunctional molecules designed to polyubiquitinate and degrade specific pathological proteins of interest (POIs) by hijacking the activity of E3-ubiquitin ligases for POI polyubiquitination and subsequent degradation by the proteasome. This strategy utilizes the ubiquitin-proteasome system for the degradation of specific proteins in the cell. In many cases, including hematologic malignancies, inducing protein degradation as a therapeutic strategy offers therapeutic benefits over classical enzyme inhibition connected with resistance to inhibitors. Limitations of small-molecule inhibitors are shown. PROTACs can polyubiquitinate and mark for degradation of "undruggable"proteins, e.g. transcription factor STAT3 and scaffold proteins. Today, this technology is used in preclinical studies in various hematologic malignancies, mainly for targeting drug-resistant bromodomain and extraterminal proteins and Bruton tyrosine kinase. Several mechanisms limiting selectivity and safety of PROTAC molecules function are also discussed.
Insights
Proteolysis targeting chimeras (PROTACs) offer a novel therapeutic strategy for hematologic malignancies by degrading disease-causing proteins. This approach overcomes limitations of traditional inhibitors, targeting even "undruggable" proteins.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Hematologic malignancies often involve aberrantly expressed or mutated proteins.
- Traditional therapies like small-molecule inhibitors and monoclonal antibodies face limitations, particularly for intracellular targets lacking active sites or antigens.
- The ubiquitin-proteasome system (UPS) is crucial for cellular protein homeostasis.
Purpose of the Study:
- To introduce proteolysis targeting chimeras (PROTACs) as a therapeutic modality for hematologic malignancies.
- To highlight the advantages of PROTACs over conventional inhibitors, especially for "undruggable" targets.
- To discuss the current preclinical applications and potential limitations of PROTAC technology in hematologic cancers.
Main Methods:
- PROTACs are bifunctional molecules that recruit E3 ubiquitin ligases to specific proteins of interest (POIs).
- This recruitment facilitates polyubiquitination of POIs, marking them for degradation by the proteasome.
- The study reviews preclinical data and discusses mechanisms of PROTAC action.
Main Results:
- PROTACs induce targeted protein degradation via the UPS, offering an alternative to enzyme inhibition.
- This strategy has shown promise in preclinical studies for hematologic malignancies, including targeting drug-resistant proteins like BET and BTK.
- PROTACs can degrade intracellular proteins previously considered "undruggable".
Conclusions:
- PROTAC technology represents a promising therapeutic strategy for hematologic malignancies, offering benefits over traditional inhibitors.
- Targeting protein degradation with PROTACs can overcome resistance mechanisms and address previously undruggable targets.
- Further research is needed to optimize PROTAC selectivity and safety for clinical application.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
